Efficacy and Safety of KH903 Plus FOLFIRI As A Second-line Treatment in Unresectable Recurrent or Metastatic Colorectal Cancer: A Randomized Phase 2 Study
Jian Li,BA YI,Rongbo Lin,Xiao Ke,Xianli yin,Jieer Ying,Ying Cheng,Nong Xu,Xu JM,Yali Shen,Zhou JF,Jufeng Wang,Xiaoping Qian,Rong wu,Yanqiao Zhang,Lin Shen
DOI: https://doi.org/10.1016/j.clcc.2024.10.003
IF: 4.035
2024-01-01
Clinical Colorectal Cancer
Abstract:Background Patients with recurrent or metastatic advanced colorectal cancer (mCRC) often face the clinical dilemma as this unresectable disease is continuously progressing and endangering the patients’ lives. In the current study, we explored the clinical feasibility of KH903 in combination with FOLFIRI chemotherapy as a new clinical indication for mCRC. Methods Patients (N=122) were randomized 1:1 to 4mg/kg q1w KH903 or 5mg/kg q2w KH903, and both groups of patients were treated with the fixed regimen of FOLFIRI (every 2 weeks) along with the KH903 therapy. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were Overall Survival (OS), objective response rate (ORR), and disease control rate (DCR). Results As of December 30, 2020, median (m)PFS was 5.68 months (95% CI,4.67-7.13) with 4mg/kg q1w vs. 5.19 months (95% CI, 4.04, 5.78) with 5mg/kg q2w (HR, 0.76; 95% CI, 0.50-1.16),and mOS was 13.14 months (95% CI, 10.61-19.52) vs. 16.03 months (95% CI, 10.28- NE), respectively (HR, 1.11; 95% CI, 0.65-1.89), The ORR was 15.9% and 11.9% for both groups, respectively, and The DCR for both groups was 85.7% and 83.1%, respectively. Grade 3 or higher treatment-related adverse event rates for both groups were 68.3% vs.52.5%, respectively. Conclusions KH903 in combination with FORFIRI in second-line treatment of patients with mCRC showed prolonged mPFS and mOS, comparing to the similar agents (Avastin®, ZALTRAP®, Cyramza®) and no new safety signals were observed. Micro Abstract In the current study, we explored the clinical feasibility of KH903 in combination with FOLFIRI chemotherapy as a new clinical indication for mCRC. We demonstrated that KH903 in combination with FORFIRI in second-line treatment of patients with mCRC showed prolonged mPFS and mOS, comparing to the similar agents. It was suggested that KH903 in combination with FOLFIRI has shown further clinical development value, and its efficacy and safety can be further confirmed in later clinical trials, providing more options for second-line treatment of metastatic colorectal cancer patients.